Pomerantz Law Firm Issues Investor Alert Regarding Vistagen Therapeutics Class Action Lawsuit

Investor Alert: Pomerantz Law Firm and Vistagen Therapeutics Class Action

On March 5, 2026, Pomerantz LLC, a well-respected law firm specialized in securities litigation, announced the filing of a class action lawsuit against Vistagen Therapeutics, Inc. (NASDAQ: VTGN). The action targets investors who may have suffered losses due to alleged securities fraud and unethical business practices within the company.

Background of Vistagen Therapeutics

Vistagen specializes in developing therapies for anxiety and depression disorders, focusing on innovating treatments that could improve the quality of life for many patients. However, recent developments have brought the company's practices under scrutiny, raising questions about its operational integrity and the accuracy of its public communications.

Details of the Lawsuit

The lawsuit is centered around a troubling announcement made by Vistagen on December 17, 2025, concerning its PALISADE-3 Phase 3 study. The study's purpose was to evaluate the efficacy of fasedienol, an intranasal treatment developed for acute social anxiety disorder. The company reported that the trial did not meet its primary endpoint, which aimed to quantify changes on the Subjective Units of Distress Scale. Consequently, no statistically significant difference was noted between those administered the drug and a placebo group, leading to a drastic decrease in Vistagen's stock price of over 80%. This stunning drop—from $3.499 per share to $0.861—has triggered alarm among investors, many of whom are now scrambling for recourse.

Your Rights as an Investor

Investors who purchased Vistagen securities during the class period are encouraged to respond promptly. The law firm advises anyone affected to reach out to Danielle Peyton at Pomerantz via email or phone, detailing their investment history and relevant contact information. A critical deadline to note: if you wish to be appointed as the Lead Plaintiff in the lawsuit, you must act before March 16, 2026. This is your chance to potentially influence the case's direction and seek restitution for your losses.

Why Pomerantz Law Firm?

Pomerantz LLP has a rich history of advocating for shareholder rights. Founded over 85 years ago by Abraham L. Pomerantz, the firm has established itself as a leading entity in securities class actions, recovering significant damages for investors who have fallen victim to corporate malpractice. Their dedication to fighting against breaches of fiduciary duty and fraudulent corporate activities has made them a trusted name in the legal landscape.

Conclusion

The unfolding situation at Vistagen Therapeutics serves as a stark reminder of the risks involved in investing, especially within the biotech sector, which can often be fraught with uncertainty. Investors are urged to stay informed, recognize their rights, and act swiftly in response to potential class action opportunities. Should you believe you have been wronged, do not hesitate to contact Pomerantz LLP to explore your legal options regarding this class action lawsuit.

For more information about the ongoing case, you can visit Pomerantz Law Firm and access the official complaint documents. Remember, timely action is crucial in these legal matters, and the window for participation in this class action is drawing close.